Clinical Trials

40 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT07464951 2026-05-27

CART123

30 enrolled

Phase 1 Active not recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT05088356 2026-05-12

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

66 enrolled

Phase EARLY_PHASE1 Recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04744116 2026-05-05

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

24 enrolled

Phase 1 Not yet recruiting

Hematologic Neoplasms

NCT07548983 2026-04-23

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

40 enrolled

Leukemia, Myeloid, Acute

NCT02131584 2026-04-16

Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia

10 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07356245 2026-04-15

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

DermatologicLymphoidOther hematologic neoplasm

44 enrolled

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

70 enrolled

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT03610971 2026-04-02

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03722407 2026-04-02

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

29 enrolled 11 charts

Leukemia, Leukemia, Myelomonocytic, Chronic

NCT03286530 2026-03-27

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

64 enrolled

Leukemia, Myeloid, Acute

NCT03874052 2026-03-24

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

51 enrolled

Leukemia, Myeloid, Acute

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

25 enrolled

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT05592015 2026-02-10

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

30 enrolled

Leukemia, Large Granular Lymphocytic

NCT07366801 2026-01-26

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

Phase 2/3 Recruiting

64 enrolled

Phase 1 Active not recruiting

Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06768476 2026-01-16

AML

12 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03571321 2026-01-09

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07128381 2026-01-05

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Phase 1/2 Recruiting

66 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

36 enrolled

Leukemia, Prolymphocytic, T-Cell

NCT07249346 2025-12-24

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Classical hematologyOther hematologic neoplasm

124 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Myelomonocytic, Chronic

NCT07297914 2025-12-22

FORUM2

Phase 2/3 Not yet recruiting

1,000 enrolled

Phase 2/3 Active not recruiting

Graft vs Host Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07238712 2025-11-20

APTBCy

60 enrolled

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT06128070 2025-10-31

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

40 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05579769 2025-10-02

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Phase 2 Terminated

3 enrolled 10 charts

Hematologic Neoplasms

NCT05745714 2025-09-16

HEM-iSMART C

Phase 1/2 Recruiting

26 enrolled

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04669210 2025-07-04

PTCyRuxo

128 enrolled

Phase 1 Active not recruiting

Graft vs Host Disease, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02494882 2025-07-02

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00674479 2025-06-15

INCB018424 in Patients With Advanced Hematologic Malignancies

51 enrolled 8 charts

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01251965 2025-06-08

Phase l/II Study of Ruxolitinib for Acute Leukemia

Phase 1/2 Terminated

27 enrolled 6 charts

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02257138 2025-06-08

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

Phase 1/2 Completed

30 enrolled 14 charts

Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT01895842 2025-02-28

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Phase 1 Completed

31 enrolled

Leukemia, Myelodysplastic Syndromes

NCT06477549 2024-06-27

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

220 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05663827 2024-03-05

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Phase 3 Completed

6 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04055844 2023-11-07

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

14 enrolled 20 charts

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05413356 2022-10-19

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

Phase 2 Unknown

50 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT01776723 2022-09-22

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Phase 1/2 Completed

50 enrolled 17 charts

Leukemia, Leukemia, Myelomonocytic, Chronic

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03041636 2021-04-21

Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1 enrolled 5 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02973711 2021-02-16

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Phase 1/2 Withdrawn

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01702064 2021-01-05

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Phase 1 Completed

11 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02092324 2020-11-16

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

51 enrolled 25 charts

Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01914484 2020-11-02

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Phase 1/2 Completed

4 enrolled